Order Article Reprints

Tsai Y-R, Kim DS, Hsueh S-C, Chen K-Y, Wu JC-C, Wang J-Y, Tsou Y-S, Hwang I, Kim Y, Gil D, et al. 3,6′- and 1,6′-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation. Pharmaceutics. 2022; 14(5):950. https://doi.org/10.3390/pharmaceutics14050950

Tsai, Yan-Rou, Dong Seok Kim, Shih-Chang Hsueh, Kai-Yun Chen, John Chung-Che Wu, Jia-Yi Wang, Yi-Syue Tsou, Inho Hwang, Yukyung Kim, Dayeon Gil, and et al. 2022. "3,6′- and 1,6′-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation" Pharmaceutics 14, no. 5: 950. https://doi.org/10.3390/pharmaceutics14050950

Tsai, Y.-R., Kim, D. S., Hsueh, S.-C., Chen, K.-Y., Wu, J. C.-C., Wang, J.-Y., Tsou, Y.-S., Hwang, I., Kim, Y., Gil, D., Jo, E. J., Han, B.-S., Tweedie, D., Lecca, D., Scerba, M. T., Selman, W. R., Hoffer, B. J., Greig, N. H., & Chiang, Y.-H. (2022). 3,6′- and 1,6′-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation. Pharmaceutics, 14(5), 950. https://doi.org/10.3390/pharmaceutics14050950